BeyondSpring Q2 Update: 58% Two-Year OS in NSCLC, DUBLIN-4 Phase 3 Planned
BYSI is trading near its 52-week low of $0.73 (12% above the low).
Summary
BeyondSpring reported Q2 2026 results and highlighted updated Phase 2 data showing a 58% two-year overall survival rate for Plinabulin combination in post-ICI NSCLC. The company also presented preclinical data supporting Plinabulin as a backbone for ADC combinations. Management confirmed DUBLIN-4, a 442-patient confirmatory Phase 3 study, as the lead priority with preparations underway. This follows the leadership transition effective July 1, 2026, with Min Qiu as CEO. The clinical data strengthens the case for Plinabulin's potential in a high-unmet-need setting, though the company remains clinical-stage with a modest market cap.
At the time of this announcement, BYSI was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.5M. The 52-week trading range was $0.73 to $2.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.